We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+23.99%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$411M
AUM Growth
+$56.5M
Cap. Flow
+$30.1M
Cap. Flow %
7.32%
Top 10 Hldgs %
65.77%
Holding
29
New
3
Increased
13
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$9.15M
2
GNMK
GenMark Diagnostics, Inc
GNMK
+$7.4M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$6.68M
4
VYGR icon
Voyager Therapeutics
VYGR
+$5.49M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.04M

Top Sells

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$19.1M
2
TSRO
TESARO, Inc.
TSRO
+$4.97M
3
OVID icon
Ovid Therapeutics
OVID
+$436K

Sector Composition

Rank Sector Weight
1 Healthcare 93.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAGE
1
DELISTED
Sage Therapeutics
SAGE
$41.2M 10.03%
250,000
+10,000
+4% +$970K
FMI
2
DELISTED
Foundation Medicine, Inc.
FMI
$35.5M 8.64%
520,000
+40,000
+8% +$2.07M
LOXO
3
DELISTED
Loxo Oncology, Inc
LOXO
$30.3M 7.38%
360,000
– –
BPMC
4
DELISTED
Blueprint Medicines
BPMC
$26.2M 6.39%
348,000
+50,000
+17% +$3.52M
BLUE
5
DELISTED
bluebird bio
BLUE
$25.8M 6.29%
11,194
– –
ALNY icon
6
Alnylam Pharmaceuticals
ALNY
$29.2B
$25.4M 6.19%
200,000
– –
MYOK
7
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$23.6M 5.74%
560,000
– –
SGMO
8
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$23M 5.59%
1,400,000
– –
GBT
9
DELISTED
Global Blood Therapeutics, Inc.
GBT
$20.3M 4.94%
515,000
+135,000
+36% +$5.04M
VYGR icon
10
Voyager Therapeutics
VYGR
$179M
$18.8M 4.59%
1,135,000
+320,000
+39% +$5.49M
AGIO icon
11
Agios Pharmaceuticals
AGIO
$1.84B
$16.9M 4.11%
295,000
+40,000
+16% +$2.52M
FATE icon
12
Fate Therapeutics
FATE
$294M
$15.9M 3.87%
2,600,000
+2,050,000
+373% +$9.15M
ONCE
13
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$15.6M 3.79%
302,474
+93,000
+44% +$6.68M
CDXS icon
14
Codexis
CDXS
$158M
$13.4M 3.25%
1,600,000
+125,000
+8% +$865K
EVH icon
15
Evolent Health
EVH
$359M
$13.3M 3.23%
1,077,500
+282,500
+36% +$3.98M
BOLD
16
DELISTED
Audentes Therapeutics, Inc
BOLD
$12.5M 3.04%
400,000
– –
GNMK
17
DELISTED
GenMark Diagnostics, Inc
GNMK
$11.4M 2.77%
2,730,000
+1,230,000
+82% +$7.4M
ILMN icon
18
Illumina
ILMN
$30.2B
$9.61M 2.34%
45,232
– –
CLVS
19
DELISTED
Clovis Oncology, Inc.
CLVS
$8.67M 2.11%
127,500
– –
JNCE
20
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$6.06M 1.47%
475,000
+75,175
+19% +$1.11M
EDIT icon
21
Editas Medicine
EDIT
$399M
$4.1M 1%
133,333
– –
CTMX icon
22
CytomX Therapeutics
CTMX
$686M
$3.75M 0.91%
177,500
– –
SYRS
23
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.67M 0.65%
27,407
+1,785
+7% +$240K
GILD icon
24
Gilead Sciences
GILD
$161B
$2.15M 0.52%
+30,000
New +$2.28M
ONC
25
BeOne Medicines Ltd
ONC
$32.3B
$1.76M 0.43%
+18,000
New +$1.65M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q4 2017 Portfolio in Review

As of Q4 2017, Casdin Capital held 29 positions worth $411M, up 16% from $354M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Casdin Capital deployed $30.1M of net new capital in Q4 2017, opening 3 new positions and adding to 13 existing holdings. Its largest new stake was Gilead Sciences: 30,000 shares worth $2.15M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 85% a quarter earlier.

On the sell side, the largest reduction was Ovid Therapeutics, an estimated $436K trimmed.

  • Casdin Capital's largest Q4 2017 buy was Gilead Sciences: 30,000 shares worth $2.15M.
  • Casdin Capital added most to Fate Therapeutics in Q4 2017, an estimated $9.15M increase.
  • Casdin Capital's biggest Q4 2017 reduction was Ovid Therapeutics, cutting an estimated $436K.
  • Casdin Capital fully exited Kite Pharma, Inc. in Q4 2017, selling an estimated $19.1M.
  • Casdin Capital's ten largest holdings make up 66% of its $411M portfolio in Q4 2017.
  • Casdin Capital opened 3 new positions and closed 2 in Q4 2017.
  • Casdin Capital's portfolio value rose 16% quarter-over-quarter to $411M.

Based on Casdin Capital's 13F filing for Q4 2017, filed 14 Feb 2018.